美国慢性骨髓单细胞白血病的生存时间趋势:基于人口的研究
Arnaud Lesegretain1,2, Andrew Brunner3, Aziz Benzohra2
1Harvard Medical School, Boston, MA, USA.
Leukemia & lymphoma
|September 15, 2023
概括
慢性骨髓 mononcytic白血病 (CMML) 的人口水平结局显示稳定的发病率和随着时间的推移改善的生存率. 然而,在黑人患者中没有观察到生存率的增加,这突出了进一步研究的关键领域.
科学领域:
- 血液学 血液学 血液学
- 流行病学 流行病学
- 在瘤学瘤学.
背景情况:
- 慢性骨髓单细胞白血病 (CMML) 的结果需要更好地了解人口水平.
- 关于CMML患者人口统计和生存趋势的流行病学数据有限.
研究的目的:
- 描述CMML患者的流行病学趋势和生存结果.
- 分析CMML发病率,人口统计和随时间的生存率的变化.
- 为了确定不同患者子组之间的生存差异.
主要方法:
- 使用了监测,流行病学和最终结果 (SEER) 计划数据库.
- 分析了2001年至2017年期间诊断的3929名CMML患者的数据.
- 将患者分为四个时间段的队列进行趋势分析.
主要成果:
- 总的来说,CMML发病率保持稳定,男性占主导地位,白人患者的发病率高于黑人和"其他"种族.
- 在2001-2004年和2014-2017年期间,三年相对存活率 (RS) 从27.9%显著提高到36.9%.
- 在大多数小组中,包括老年人 (85岁以上) 和长期幸存者 (5年生存率从13.2%增加到22.3%),但黑人患者没有改善生存率.
结论:
- 随着时间的推移,CMML患者的治疗结果有所改善,大多数人口群体的生存率有所增加.
- 仍然存在显著的差异,特别是黑人CMML患者的生存率没有改善.
- 进一步的研究对于了解和解决导致黑人CMML患者表现不佳的因素至关重要.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
08:00A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
20.2K
相关概念视频
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
01:24Kaplan-Meier Approach
178
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
178